GE Healthcare and Optellum join forces to advance Lung Cancer Diagnosis with Artificial Intelligence
November 29, 2021
DART partners GE Healthcare and Optellum announced that they have signed a letter of intent to collaborate to advance precision diagnosis and treatment of lung cancer. GE Healthcare is a global leader in medical imaging solutions. Optellum is the leader in AI decision support for the early diagnosis and optimal treatment of lung cancer.
A clinician’s AI-assisted diagnosis of malignancy may enable patients whose nodules are not malignant to avoid unnecessary and aggressive procedures such as biopsy and surgical resection, while expediting the diagnostic process, and enabling the right treatment to start earlier. This has the potential to provide patients with personalized diagnosis and treatment plans, enabling lung cancer patients to be treated at the earliest possible stage when survival rates are the highest. This is also the ambition of DART.
Read the full press release here.

Important: DART Programme Data Email Address Update
March 17, 2025
Thank you to all the sites which are sending data to the DART Programme. Please note that our email address…
Update on the NHS Lung Cancer Screening Programme
March 4, 2025

DART at OxCODE
January 29, 2025
Active data enrichment by learning what to annotate in digital pathology
March 11, 2024